Preclinical studies have demonstrated that trimetrexate is a potent inhibitor of dihydrofolate reductase from Pneumocystis carinii. On the basis of this evidence, this lipid-soluble antifolate was used as an antipneumocystis agent in 49 patients with the acquired immunodeficiency syndrome (AIDS) and pneumocystis pneumonia. Simultaneous treatment with the reduced folate leucovorin was used as a specific antidote to protect host tissues from the toxic effects of the antifolate without affecting the antipneumocystis action of trimetrexate. Patients were assigned to three groups and treated for 21 days: in Group I, trimetrexate with leucovorin was used as salvage therapy in patients in whom standard treatments (both pentamidine isethionate and trimethoprim-sulfamethoxazole) could not be tolerated or had failed (16 patients); in Group II, trimetrexate with leucovorin was used as initial therapy in patients with a history of sulfonamide inefficacy or intolerance (16 patients); and in Group III, trimetrexate with leucovorin plus sulfadiazine was used as initial therapy (17 patients). The response and survival rates were, respectively, 69 percent and 69 percent in Group I; 63 percent and 88 percent in Group II; and 71 percent and 77 percent in Group III. Trimetrexate therapy had minimal toxicity; transient neutropenia or thrombocytopenia occurred in 12 patients and mild elevation of serum aminotransferases in 4. We conclude that the combination of trimetrexate and leucovorin is safe and effective for the initial treatment of pneumocystis pneumonia in patients with AIDS and for the treatment of patients with intolerance or lack of response to standard therapies.
Source Information
National Cancer Institute, Clinical Center, Bethesda, MD 20892.
This article has been cited by other articles:
Liu, J., Bolstad, D. B., Bolstad, E. S. D., Wright, D. L., Anderson, A. C.
(2009). Towards New Antifolates Targeting Eukaryotic Opportunistic Infections. Eukaryot Cell
8: 483-486
[Abstract][Full Text]
Robien, K.
(2005). Folate During Antifolate Chemotherapy: What We Know... and Do Not Know. Nutr Clin Pract
20: 411-422
[Abstract][Full Text]
Di Rocco, A., Bottiglieri, T., Werner, P., Geraci, A., Simpson, D., Godbold, J., Morgello, S.
(2002). Abnormal cobalamin-dependent transmethylation in AIDS-associated myelopathy. Neurology
58: 730-735
[Abstract][Full Text]
Smego, R. A. Jr, Nagar, S., Maloba, B., Popara, M.
(2001). A Meta-analysis of Salvage Therapy for Pneumocystis carinii Pneumonia. Arch Intern Med
161: 1529-1533
[Abstract][Full Text]
Purdy, B. D.
(2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice
13: 475-498
[Abstract]
Ma, L., Kovacs, J. A.
(2000). Expression and Characterization of Recombinant Human-Derived Pneumocystis carinii Dihydrofolate Reductase. Antimicrob. Agents Chemother.
44: 3092-3096
[Abstract][Full Text]
Fishman, J. A.
(1998). Treatment of Infection Due to Pneumocystis carinii. Antimicrob. Agents Chemother.
42: 1309-1314
[Full Text]
Gorlick, R., Goker, E., Trippett, T., Waltham, M., Banerjee, D., Bertino, J. R.
(1996). Intrinsic and Acquired Resistance to Methotrexate in Acute Leukemia. NEJM
335: 1041-1048
[Full Text]
Bertino, J.R., Goker, E., Gorlick, R., Li, W.W., Banerjee, D.
(1996). Resistance Mechanisms to Methotrexate in Tumors. The Oncologist
1: 223-226
[Abstract][Full Text]
Takimoto, C. H.
(1996). New Antifolates: Pharmacology and Clinical Applications. The Oncologist
1: 68-81
[Abstract][Full Text]
(1992). Equal Survival Rates for First, Second, and Third Episodes of Pneumocystis carinii Pneumonia in Patients With Acquired Immunodeficiency Syndrome: Michael N. Dohn, MD; Robert P. Baughman, MD; Ellen M. Vigdorth, PhD; Diana L. Frame. Arch Intern Med
152: 2465-2470
[Abstract]
Wachter, R. M., Luce, J. M., Hopewell, P. C.
(1992). Critical Care of Patients With AIDS. JAMA
267: 541-547
[Abstract]
Friedman, Y., Franklin, C., Freels, S., Weil, M. H.
(1991). Long-term Survival of Patients With AIDS, Pneumocystis carinii Pneumonia, and Respiratory Failure. JAMA
266: 89-92
[Abstract]
Pluda, J. M., Yarchoan, R., Jaffe, E. S., Feuerstein, I. M., Solomon, D., Steinberg, S. M., Wyvill, K. M., Raubitschek, A., Katz, D., Broder, S.
(1990). Development of Non-Hodgkin Lymphoma in a Cohort of Patients with Severe Human Immunodeficiency Virus (HIV) Infection on Long-Term Antiretroviral Therapy. ANN INTERN MED
113: 276-282
[Abstract]
Glatt, A. E., Chirgwin, K.
(1990). Pneumocystis carinii Pneumonia in Human Immunodeficiency Virus-Infected Patients. Arch Intern Med
150: 271-279
[Abstract]
Fried, J. C., LoPresti, J. S., Micon, M., Bauer, M., Tuchschmidt, J. A., Nicoloff, J. T.
(1990). Serum Triiodothyronine Values: Prognostic Indicators of Acute Mortality due to Pneumocystis carinii Pneumonia Associated With the Acquired Immunodeficiency Syndrome. Arch Intern Med
150: 406-409
[Abstract]
Masur, H., Lane, H. C., Kovacs, J. A., Allegra, C. J., Edman, J. C.
(1989). Pneumocystis Pneumonia: From Bench to Clinic. ANN INTERN MED
111: 813-826
[Abstract]
Armstrong, D., Bernard, E.
(1988). Aerosol Pentamidine. ANN INTERN MED
109: 852-854
[Abstract]
Sattler, F. R., Cowan, R., Nielsen, D. M., Ruskin, J.
(1988). Trimethoprim-Sulfamethoxazole Compared with Pentamidine for Treatment of Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency Syndrome: A Prospective, Noncrossover Study. ANN INTERN MED
109: 280-287
[Abstract]
(1987). A NEW TREATMENT FOR PNEUMOCYSTIS PNEUMONIA. JWatch General
1987: 1-1
[Full Text]
Previous
